These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 29296532)

  • 1. A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of Vγ9Vδ2-T cells.
    de Bruin RCG; Veluchamy JP; Lougheed SM; Schneiders FL; Lopez-Lastra S; Lameris R; Stam AG; Sebestyen Z; Kuball J; Molthoff CFM; Hooijberg E; Roovers RC; Santo JPD; van Bergen En Henegouwen PMP; Verheul HMW; de Gruijl TD; van der Vliet HJ
    Oncoimmunology; 2017; 7(1):e1375641. PubMed ID: 29296532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Bispecific Single-Domain Antibody Boosts Autologous Vγ9Vδ2-T Cell Responses Toward CD1d in Chronic Lymphocytic Leukemia.
    de Weerdt I; Lameris R; Ruben JM; de Boer R; Kloosterman J; King LA; Levin MD; Parren PWHI; de Gruijl TD; Kater AP; van der Vliet HJ
    Clin Cancer Res; 2021 Mar; 27(6):1744-1755. PubMed ID: 33451981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Highly specific and potently activating Vγ9Vδ2-T cell specific nanobodies for diagnostic and therapeutic applications.
    de Bruin RCG; Lougheed SM; van der Kruk L; Stam AG; Hooijberg E; Roovers RC; van Bergen En Henegouwen PMP; Verheul HMW; de Gruijl TD; van der Vliet HJ
    Clin Immunol; 2016 Aug; 169():128-138. PubMed ID: 27373969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Bispecific γδ T-cell Engager Targeting EGFR Activates a Potent Vγ9Vδ2 T cell-Mediated Immune Response against EGFR-Expressing Tumors.
    King LA; Toffoli EC; Veth M; Iglesias-Guimarais V; Slot MC; Amsen D; van de Ven R; Derks S; Fransen MF; Tuynman JB; Riedl T; Roovers RC; Adang AEP; Ruben JM; Parren PWHI; de Gruijl TD; van der Vliet HJ
    Cancer Immunol Res; 2023 Sep; 11(9):1237-1252. PubMed ID: 37368791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of Vγ9Vδ2 T Cell Activation by a Vγ9Vδ2 TCR Nanobody.
    de Bruin RC; Stam AG; Vangone A; van Bergen En Henegouwen PM; Verheul HM; Sebestyén Z; Kuball J; Bonvin AM; de Gruijl TD; van der Vliet HJ
    J Immunol; 2017 Jan; 198(1):308-317. PubMed ID: 27895170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CRTAM receptor engagement by Necl-2 on tumor cells triggers cell death of activated Vγ9Vδ2 T cells.
    Dessarthe B; Thedrez A; Latouche JB; Cabillic F; Drouet A; Daniel P; de La Pintière CT; Catros V; Toutirais O
    J Immunol; 2013 May; 190(9):4868-76. PubMed ID: 23530148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repeated systemic administrations of both aminobisphosphonates and human Vγ9Vδ2 T cells efficiently control tumor development in vivo.
    Santolaria T; Robard M; Léger A; Catros V; Bonneville M; Scotet E
    J Immunol; 2013 Aug; 191(4):1993-2000. PubMed ID: 23836057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A bispecific T cell engager recruits both type 1 NKT and Vγ9Vδ2-T cells for the treatment of CD1d-expressing hematological malignancies.
    Lameris R; Ruben JM; Iglesias-Guimarais V; de Jong M; Veth M; van de Bovenkamp FS; de Weerdt I; Kater AP; Zweegman S; Horbach S; Riedl T; Winograd B; Roovers RC; Adang AEP; de Gruijl TD; Parren PWHI; van der Vliet HJ
    Cell Rep Med; 2023 Mar; 4(3):100961. PubMed ID: 36868236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adoptive transfer of ex vivo expanded Vγ9Vδ2 T cells in combination with zoledronic acid inhibits cancer growth and limits osteolysis in a murine model of osteolytic breast cancer.
    Zysk A; DeNichilo MO; Panagopoulos V; Zinonos I; Liapis V; Hay S; Ingman W; Ponomarev V; Atkins G; Findlay D; Zannettino A; Evdokiou A
    Cancer Lett; 2017 Feb; 386():141-150. PubMed ID: 27865798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthetic phosphoantigens enhance human Vgamma9Vdelta2 T lymphocytes killing of non-Hodgkin's B lymphoma.
    Sicard H; Al Saati T; Delsol G; Fournié JJ
    Mol Med; 2001 Oct; 7(10):711-22. PubMed ID: 11713370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Production of TNF-alpha by human V gamma 9V delta 2 T cells via engagement of Fc gamma RIIIA, the low affinity type 3 receptor for the Fc portion of IgG, expressed upon TCR activation by nonpeptidic antigen.
    Lafont V; Liautard J; Liautard JP; Favero J
    J Immunol; 2001 Jun; 166(12):7190-9. PubMed ID: 11390467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-21-mediated potentiation of antitumor cytolytic and proinflammatory responses of human V gamma 9V delta 2 T cells for adoptive immunotherapy.
    Thedrez A; Harly C; Morice A; Salot S; Bonneville M; Scotet E
    J Immunol; 2009 Mar; 182(6):3423-31. PubMed ID: 19265120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ex vivo characterization of γδ T-cell repertoire in patients after adoptive transfer of Vγ9Vδ2 T cells expressing the interleukin-2 receptor β-chain and the common γ-chain.
    Izumi T; Kondo M; Takahashi T; Fujieda N; Kondo A; Tamura N; Murakawa T; Nakajima J; Matsushita H; Kakimi K
    Cytotherapy; 2013 Apr; 15(4):481-91. PubMed ID: 23391461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL-21 Increases the Reactivity of Allogeneic Human Vγ9Vδ2 T Cells Against Primary Glioblastoma Tumors.
    Joalland N; Chauvin C; Oliver L; Vallette FM; Pecqueur C; Jarry U; Scotet E
    J Immunother; 2018 Jun; 41(5):224-231. PubMed ID: 29683891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gamma Delta T Cell Therapy for Cancer: It Is Good to be Local.
    Pauza CD; Liou ML; Lahusen T; Xiao L; Lapidus RG; Cairo C; Li H
    Front Immunol; 2018; 9():1305. PubMed ID: 29937769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potentiation of antigen-stimulated V gamma 9V delta 2 T cell cytokine production by immature dendritic cells (DC) and reciprocal effect on DC maturation.
    Devilder MC; Maillet S; Bouyge-Moreau I; Donnadieu E; Bonneville M; Scotet E
    J Immunol; 2006 Feb; 176(3):1386-93. PubMed ID: 16424165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activated iNKT cells promote Vγ9Vδ2-T cell anti-tumor effector functions through the production of TNF-α.
    Schneiders FL; de Bruin RC; Santegoets SJ; Bonneville M; Scotet E; Scheper RJ; Verheul HM; de Gruijl TD; van der Vliet HJ
    Clin Immunol; 2012 Feb; 142(2):194-200. PubMed ID: 22122798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human Vgamma9Vdelta2 T cells: promising new leads for immunotherapy of infections and tumors.
    Bonneville M; Scotet E
    Curr Opin Immunol; 2006 Oct; 18(5):539-46. PubMed ID: 16870417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human Vgamma9Vdelta2 T cells: from signals to functions.
    Nedellec S; Bonneville M; Scotet E
    Semin Immunol; 2010 Aug; 22(4):199-206. PubMed ID: 20447835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD70-CD27 interactions provide survival and proliferative signals that regulate T cell receptor-driven activation of human γδ peripheral blood lymphocytes.
    DeBarros A; Chaves-Ferreira M; d'Orey F; Ribot JC; Silva-Santos B
    Eur J Immunol; 2011 Jan; 41(1):195-201. PubMed ID: 21182090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.